BACKGROUND/AIMS: Combination therapy with peginterferon and ribavirin is a standard therapy for western patients with chronic hepatitis C; however, its efficacy remains unclear in East Asian patients. We evaluated the efficacy and safety of administering peginterferon alfa-2a plus ribavirin in native Korean patients with chronic hepatitis C. METHODS: Seventy-five patients with detectable HCV RNA (52.0% male, median age: 50.8 years) were eligible for the study. The patients were treated with peginterferon alfa-2a 180 mcg/week plus ribavirin 800 mg/day for 24 weeks (for genotype non-1, n=46) or 1000-1200 mg/day for 48 weeks (for genotype 1, n=29). The early virologic response (EVR), the end of treatment virologic response (ETVR), the sustained virologic response (SVR), the biochemical response and the adverse event were analyzed. RESULTS: EVR was seen in 86.2% of the patients with genotype 1. The ETVR was 58.6% in the genotype 1 group and 84.8% in the genotype non-1 group (P=0.02). The overall SVR was 70.7%: 55.2% in the genotype 1 group and 80.4% in the non-1 group (P=0.04). The sustained biochemical response was 64.0%. Multivariate analysis showed that the baseline HCV RNA level (Odds ratio: 0.045, 95% CI: 0.011-0.183, P<0.001) and genotype (Odds ratio: 0.247, 95% CI: 0.063-0.969, P=0.045) had an independent effect on the SVR. Neutropenia, anemia, flu-like symptoms and itching were the common adverse events. Aggravated liver function led to discontinuation of therapy for six patients. Dose modification in twenty-nine patients was effective without producing a significant reduction of the SVR. CONCLUSIONS: Our data suggest that the efficacy of peginterferon plus ribavirin therapy in Koreans is comparable to those from studies on Western patients as an initial treatment for chronic hepatitis C patients. The baseline HCV RNA level and the genotype can be significant factors influencing the SVR.
BACKGROUND/AIMS: Combination therapy with peginterferon and ribavirin is a standard therapy for western patients with chronic hepatitis C; however, its efficacy remains unclear in East Asian patients. We evaluated the efficacy and safety of administering peginterferon alfa-2a plus ribavirin in native Korean patients with chronic hepatitis C. METHODS: Seventy-five patients with detectable HCV RNA (52.0% male, median age: 50.8 years) were eligible for the study. The patients were treated with peginterferon alfa-2a 180 mcg/week plus ribavirin 800 mg/day for 24 weeks (for genotype non-1, n=46) or 1000-1200 mg/day for 48 weeks (for genotype 1, n=29). The early virologic response (EVR), the end of treatment virologic response (ETVR), the sustained virologic response (SVR), the biochemical response and the adverse event were analyzed. RESULTS: EVR was seen in 86.2% of the patients with genotype 1. The ETVR was 58.6% in the genotype 1 group and 84.8% in the genotype non-1 group (P=0.02). The overall SVR was 70.7%: 55.2% in the genotype 1 group and 80.4% in the non-1 group (P=0.04). The sustained biochemical response was 64.0%. Multivariate analysis showed that the baseline HCV RNA level (Odds ratio: 0.045, 95% CI: 0.011-0.183, P<0.001) and genotype (Odds ratio: 0.247, 95% CI: 0.063-0.969, P=0.045) had an independent effect on the SVR. Neutropenia, anemia, flu-like symptoms and itching were the common adverse events. Aggravated liver function led to discontinuation of therapy for six patients. Dose modification in twenty-nine patients was effective without producing a significant reduction of the SVR. CONCLUSIONS: Our data suggest that the efficacy of peginterferon plus ribavirin therapy in Koreans is comparable to those from studies on Western patients as an initial treatment for chronic hepatitis Cpatients. The baseline HCV RNA level and the genotype can be significant factors influencing the SVR.
Authors: Chansoo Moon; Kyu Sik Jung; Do Young Kim; Oidov Baatarkhuu; Jun Yong Park; Beom Kyung Kim; Seung Up Kim; Sang Hoon Ahn; Kwang-Hyub Han Journal: Dig Dis Sci Date: 2014-09-19 Impact factor: 3.199
Authors: Nghia H Nguyen; Shelley A McCormack; Philip Vutien; Brittany E Yee; Pardha Devaki; David Jencks; Mindie H Nguyen Journal: Intervirology Date: 2015-01-10 Impact factor: 1.763
Authors: Sang Hoon Park; Choong Kee Park; Jin Woo Lee; Young Seok Kim; Sook-Hyang Jeong; Yun Soo Kim; Ju Hyun Kim; Seong Gyu Hwang; Kyu Sung Rim; Hyung Joon Yim; Jae Youn Cheong; Sung Won Cho; June Sung Lee; Young Min Park; Jeong Won Jang; Chun Kyon Lee; Joo Hyun Shon; Jin Mo Yang; Young Soo Ju Journal: Gut Liver Date: 2012-01-12 Impact factor: 4.519
Authors: Yu Jin Kim; Jin Woo Lee; Yun Soo Kim; Sook Hyang Jeong; Young Seok Kim; Hyung Joon Yim; Bo Hyun Kim; Chun Kyon Lee; Choong Kee Park; Sang Hoon Park Journal: Korean J Hepatol Date: 2011-09
Authors: Jung Hyun Kwon; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Kwan Soo Byun; Seung Woon Paik; Young Suk Lim; Han Chu Lee; Kwang Hyub Han; Kwan Sik Lee Journal: Korean J Intern Med Date: 2009-08-26 Impact factor: 3.165
Authors: Byung Chul You; Young Seok Kim; Hun il Kim; Se Hun Kim; Seung Sik Park; Yu Ri Seo; Sang Gyune Kim; Se Whan Lee; Hong Soo Kim; Soung Won Jeong; Jae Young Jang; Boo Sung Kim Journal: Clin Mol Hepatol Date: 2012-09-25